Producătorii unor populare medicamente pentru slăbit, război în instanță. De la ce a pornit râca dintre companiile care fac Wegovy, Ozempic, Mounjaro și Zepbound

Novo Nordisk has filed a lawsuit against Eli Lilly, claiming misleading advertising regarding obesity medications. The Danish company seeks a court order to stop Eli Lilly's ads, asserting they misrepresent product comparisons. Eli Lilly denies any wrongdoing and plans to defend its advertising campaign. The dispute highlights the competitive landscape of the obesity drug market, projected to exceed $100 billion in the U.S. by the decade's end. Analysts suggest Novo's legal action aims to influence public perception, though some believe it may not aid their marketing efforts.